Prosangvis - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 946,840 | 669,503 | 97,761 | 69,515 | 41,177 | 34,259 | 11,915 | 9,056 |
| Profit before tax | -36,052 | 12,569 | -26,888 | -8,371 | -3,480 | -5,617 | -6,006 | 5,172 |
| Net profit | -36,052 | 11,993 | -26,888 | -8,371 | -3,480 | -5,617 | -6,006 | 5,172 |
| Equity | 143,305 | 155,298 | 128,410 | 120,039 | 116,559 | 110,942 | 104,936 | 100,636 |
| Liabilities | 269,247 | 160,085 | 54,484 | 24,749 | 24,290 | 27,849 | 23,032 | 23,733 |
| Non-current assets | 26,550 | 22,328 | 22,416 | 11,879 | 6,255 | 1,738 | 105 | 105 |
| Current assets | 385,778 | 292,881 | 160,333 | 132,905 | 134,590 | 137,048 | 127,858 | 124,263 |
| Total assets | 412,328 | 315,209 | 182,749 | 144,784 | 140,845 | 138,786 | 127,963 | 124,368 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 6,497 | 4,260 | 2,812 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +20.9% | -29.3% | -85.4% | -28.9% | -40.8% | -16.8% | -65.2% | -24.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -8.7% | 3.8% | -14.7% | -5.8% | -2.5% | -4.0% | -4.7% | 4.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -25.2% | 7.7% | -20.9% | -7.0% | -3.0% | -5.1% | -5.7% | 5.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -3.8% | 1.8% | -27.5% | -12.0% | -8.5% | -16.4% | -50.4% | 57.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -3.8% | 1.9% | -27.5% | -12.0% | -8.5% | -16.4% | -50.4% | 57.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.9 | 1.0 | 0.4 | 0.2 | 0.2 | 0.3 | 0.2 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 183,258 | 365,190 | 61,745 | 34,758 | 20,589 | 17,130 | 5,958 | 6,037 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Prosangvis - Social security debts
The company had no debts to Sodra
Prosangvis - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Prosangvis, UAB (code 300089105) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €9.1K and net profit of €5.2K, resulting in a profit margin of 57.1%. This followed two loss-making years: in 2024 revenue was €11.9K with a net loss of €6.0K, and in 2023 revenue was €34.3K with a net loss of €5.6K. Over the two-year period from 2023 to 2025, revenue declined by 73.6%, showing a significant contraction in turnover. At the same time, profitability improved sharply in 2025 after the losses recorded in the previous years. As of 2025, total assets stood at €124.4K, equity at €100.6K, and liabilities at €23.7K. The equity ratio was 80.9% and debt-to-equity 0.24, indicating a strongly equity-funded balance sheet. Asset turnover was 0.07x, and revenue per employee was €9.1K.